CAR T-cell therapy with Dr. Mazyar Shadman
Échec de l'ajout au panier.
Veuillez réessayer plus tard
Échec de l'ajout à la liste d'envies.
Veuillez réessayer plus tard
Échec de la suppression de la liste d’envies.
Veuillez réessayer plus tard
Échec du suivi du balado
Ne plus suivre le balado a échoué
CAR T-cell therapy with Dr. Mazyar Shadman
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Dr. Mazyar Shadman is a blood cancer specialist at Fred Hutch Cancer Center who focuses on lymphoid malignancies. In a conversation with Bonnie Rochman, they explore the advancements in CAR T-cell therapy, particularly for large B-cell lymphoma, highlighting its impact on patient outcomes and survival rates.
Takeaways
- CAR T therapy is a significant advancement in cancer treatment.
- The future of cancer treatment may heavily rely on CAR T advancements.
- CAR T therapy represents a shift in cancer care paradigms.
- It is particularly effective for large B-cell lymphoma.
- Patients with relapsed disease historically had limited survival chances.
- CAR T therapy has improved outcomes for high-risk patients.
- 30 to 40% of patients are now being cured with CAR T therapy.
- The treatment offers better quality of life compared to standard care.
- Ongoing research is crucial for further advancements in CAR T.
- Patient selection is key for the success of CAR T therapy.
Pas encore de commentaire